A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
CONTEXT: Classic congenital adrenal hyperplasia (CAH) management remains challenging, given that supraphysiologic glucocorticoid doses are often needed to optimally suppress the ACTH-driven adrenal androgen overproduction. OBJECTIVE: This study sought to approximate physiologic cortisol secretion via continuous subcutaneous hydrocortisone infusion (CSHI) and evaluate the safety and efficacy of CSHI in patients with difficult-to-treat CAH. DESIGN: Eight adult patients with classic CAH participated in a single-center open-label phase I-II study comparing CSHI to conventional oral glucocorticoid treatment. All patients had elevated adrenal steroids and one or more comorbidities at study entry. Assessment while receiving conventional therapy at baseline and 6 months following CSHI included: 24-hour hormonal sampling, metabolic and radiologic evaluation, health-related quality-of-life (HRQoL), and fatigue questionnaires. MAIN OUTCOME MEASURES: The ability of CSHI to approximate physiologic cortisol secretion and the percent of patients with 0700-hour 17-hydroxyprogesterone (17-OHP) ≤1200 ng/dL was measured. RESULTS: CSHI approximated physiologic cortisol secretion. Compared with baseline, 6 months of CSHI resulted in decreased 0700-hour and 24-hour area under the curve 17-OHP, androstenedione, ACTH, and progesterone, increased osteocalcin, c-telopeptide and lean mass, and improved HRQoL (and SF-36 Vitality Score), and fatigue. One of three amenorrheic women resumed menses. One man had reduction of testicular adrenal rest tissue. CONCLUSIONS: CSHI is a safe and well-tolerated modality of cortisol replacement that effectively approximates physiologic cortisol secretion in patients with classic CAH poorly controlled on conventional therapy. Improved adrenal steroid control and positive effects on HRQoL suggest that CSHI should be considered a treatment option for classic CAH. The long-term effect on established comorbidities requires further study.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Continuous subcutaneous hydrocortisone infusion (CSHI) that approximates circadian cortisol secretion was previously shown to improve disease control in patients with 21OHD poorly controlled with OG therapy based on the traditional biomarkers 17OHP and A4 (7).”
In the citing paper
“Infants prenatally exposed to betamethasone have altered responses of the HPA axis and a higher incidence of mental and behavioral disorders (490,491).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [491]
In the citing paper
“and showed improved quality-of-life and fatigue in 8 patients with classic 21-OH deficiency.142”
From Congenital adrenal hyperplasia (2017) · cites this paper as [142]
In the citing paper
“Long-standing comorbidities, such as insulin resistance and TART, remained mostly unchanged by 6 months”
From Congenital adrenal hyperplasia (2017) · cites this paper as [142]
In the citing paper
“Continuous subcutaneous hydrocortisone infusion via an insulin pump mimicking cortisol circadian rhythm, has similarly shown adequate ACTH suppression with lower total hydrocortisone dose compared to conventional treatment, 139-142”
From Congenital adrenal hyperplasia (2017) · cites this paper as [142]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 1×
“5 (18, 19)], osteopenia or osteoporosis (BMD T-score –1), or glucocorticoid-related gastrointestinal (GI) side effects.”
BackgroundOverview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project
Ware, J. E., & Gandek, B. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00081-x · Cited by 2,605 · cited 1×
“SF-36 score was calculated using the SF-36 OptumInsight software which provides norm-based scores and applies a linear T-score transformation (mean 50, SD 10) (22, 26).”
MethodSpeiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468 · cited 2×
“(1) Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA 20892; (2) National Institutes of Health Clinical Center, Bethesda MD, USA 20892”
BackgroundSelf-citationUltrasound scanning in the detection of hepatic fibrosis and steatosis.
Saverymuttu, S. H., Joseph, A. E., & Maxwell, J. D. (1986) · BMJ · doi:10.1136/bmj.292.6512.13 · Cited by 853 · cited 1×
“0 kg/m(2)], fatty liver disease [AST to ALT ratio 1 (16) and/or steatosis per liver ultrasound (17)], low insulin sensitivity [Homeostasis Model Assessment Insulin Resistance (HOMA-IR) 2.”
BackgroundCongenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Self-citationHealth status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients
Arlt, W., Willis, D. S., Wild, S. H., Krone, N., Doherty, E. J., Hahner, S., Han, T. S., Carroll, P. V., Conway, G. S., Rees, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0917 · Cited by 506 · cited 2×
“(1) Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA 20892; (2) National Institutes of Health Clinical Center, Bethesda MD, USA 20892”
BackgroundAscaso, J. F., Pardo, S., Real, J. T., Lorente, R. I., Priego, A., & Carmena, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3320 · Cited by 490 · cited 1×
“5 (18, 19)], osteopenia or osteoporosis (BMD T-score –1), or glucocorticoid-related gastrointestinal (GI) side effects.”
BackgroundSorbi, D. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00061-1 · Cited by 466 · cited 1×
“0 kg/m(2)], fatty liver disease [AST to ALT ratio 1 (16) and/or steatosis per liver ultrasound (17)], low insulin sensitivity [Homeostasis Model Assessment Insulin Resistance (HOMA-IR) 2.”
BackgroundComparison of self-reported fatigue in rheumatoid arthritis and controls.
Bl, B. (1995) · PubMed · Cited by 355
Modified-release hydrocortisone to provide circadian cortisol profiles
Debono, M., Ghobadi, C., Rostami-Hodjegan, A., Huatan, H., Campbell, M. J., Newell-Price, J., Darzy, K., Merke, D. P., Arlt, W., & Ross, R. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2380 · Cited by 322 · cited 5×
“Rates were established to achieve peak and trough concentrations within the normal circadian cortisol range based on an estimate of the mean in healthy controls (6) and by using the formula [Infusion Rate (mg/24hrs) clearance (mL/24hr) x target cortisol concentration (mg/mL)].”
BackgroundMethodResultInfluentialSelf-citation
Cited by
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationCongenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Self-citationCongenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationCongenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341
Self-citationHahner, S., Ross, R. J., Arlt, W., Bancos, I., Burger-Stritt, S., Torpy, D. J., Husebye, E. S., & Quinkler, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00252-7 · Cited by 223
Metadata
- Authors
- Nella, A. A., Mallappa, A., Perritt, A. F., Gounden, V., Kumar, P., Sinaii, N., Daley, L.-A., Ling, A., Liu, C.-Y., Soldin, S. J., & Merke, D. P.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Nella, Aikaterini A.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-12
- Volume
- 101
- Issue
- 12
- Pages
- 4690-4698
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC5155681
- OpenAlex
- W2524670571
- Cited by
- 91
- References
- 30
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 12 · 2023: 5 · 2022: 11 · 2021: 10 · 2020: 8 · 2019: 9 · 2018: 13 · 2017: 11
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- congenital adrenal hyperplasia, cortisol replacement therapy, 17-hydroxyprogesterone, ACTH, health-related quality of life, fatigue, bone mineral density, amenorrhea, adults
- MeSH terms
- Adrenal Hyperplasia, Congenital, Adult, Female, Glucocorticoids, Humans, Hydrocortisone, Male, Biomarkers, Outcome Assessment, Health Care, Hormone Replacement Therapy, Infusions, Subcutaneous, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia. https://app.cochat.ai/papers/10.1210/jc.2016-1916
- The paper
- Nella, A. A., Mallappa, A., Perritt, A. F., Gounden, V., Kumar, P., Sinaii, N., Daley, L.-A., Ling, A., Liu, C.-Y., Soldin, S. J., & Merke, D. P. (2016). A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2016-1916
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.